MIMS March Prescribing Update

- Aubagio (teriflunomide) an oral immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but may include reduced number of activated lymphocytes in the CNS. Aubagio is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability. Aubagio is contraindicated in patients with hypersensitivity to leflunomide, teriflunomide; patients with severe immunodeficiency states, e.g. AIDS; patients with significantly impaired bone marrow function or significant anaemia, leucopenia or thrombocytopenia; patients with severe, uncontrolled infections; patients with severe impairment of liver function; pregnant women; women